⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Table S2 from Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial

David S. Hong Michael A. Postow Bartosz Chmielowski Ryan J. Sullivan Amita Patnaik Ezra E.W. Cohen Geoffrey I. Shapiro Conor Steuer Martin Gutierrez Heather Yeckes-Rodin Robert Ilaria Brenda O’Connell Joanna Peng Guangbin Peng Nora Zizlsperger Anthony W. Tolcher Jedd D. Wolchok

View at Publisher

Ask AI

Bookmark

Share

Abstract

Summary of anti-tumor activity endpoints in patients treated with eganelisib monotherapy and combination therapy

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hong et al. (2024) studied this question.

synapsesocial.com/papers/68e586b5b6db643587522fe9 https://doi.org/10.1158/1078-0432.27030661

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S2 from Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial2024
2Table S3 from Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial2024
3Table S3 from Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial2024
4Table S1 from Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial2024
5Table S1 from Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial2024

More related papers

Table S4 from Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial2024
Table S4 from Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial2024
Data from Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial2024